Activation of FGF Receptors is a new Mechanism by which Strontium Ranelate Induces Osteoblastic Cell Growth

Abstract
Strontium ranelate (SrRan) is an anti-osteoporotic treatment that reduces the risk of vertebral and hip fractures. Recent in vitro studies suggest that the effect of strontium ranelate on osteoblastic cell growth likely involves two processes including activation of the calcium sensing receptor (CaSR) and a yet undefined mechanism. In the present study, we investigated the CaSR-independent molecular mechanism by which SrRan stimulates osteoblast growth

This publication has 30 references indexed in Scilit: